this is what the company is reporting for TriAb.......
biz.yahoo.com
TriAb was administered on a weekly basis for three weeks, starting
one week after chemotherapy, and then continued monthly following stem cell transplantation for up to 24 months. A strong
immune response against the breast cancer antigen, HMFG, was demonstrated in 20 of 21 patients. Seventeen patients have no
evidence of disease progression at a median of 4 months (range 1-12 months). None of the treated patients experienced any
significant adverse effects from treatment with the vaccine.
''Titan has previously demonstrated that its cancer vaccines can be used in conjunction with other current standard treatments,
such as chemotherapy with 5FU, leucovorin, or irinotecan for colon cancer, and radiation therapy for lung cancer,'' explained
Dr. April Teitelbaum, Sr. Director of Clinical Research at Titan. ''In patients with impaired immune systems, this can be
potentially challenging. The swift generation of anti-HMFG cancer antigen immune responses by TriAb in patients following
bone marrow transplantation, which typically suppresses the immune system, is therefore quite impressive.'' |
